Literature DB >> 31662318

Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition.

Jian Yin1, Peter Richard Sternes2, Matthew A Brown3, Huji Xu4,5,6, Mingbang Wang7, Jing Song1, Mark Morrison8, Ting Li1, Ling Zhou1, Xin Wu1, Fusheng He9, Jian Zhu5.   

Abstract

OBJECTIVES: Diverse evidence including clinical, genetic and microbiome studies support a major role of the gut microbiome in the common immune-mediated arthropathy, ankylosing spondylitis (AS). We set out to (1) further define the key microbial characteristics driving disease, and (2) examine the effects of tumour necrosis factor-inhibitor (TNFi) therapy upon the microbiome.
METHODS: The stools from a case-control cohort of 250 Han-Chinese subjects underwent shotgun metagenomic sequencing. All subjects were genotyped using the Illumina CoreExome SNP microarray.
RESULTS: Previous reports of gut dysbiosis in AS were reconfirmed and several notable bacterial species and functional categories were differentially abundant. TNFi therapy was correlated with a restoration the perturbed microbiome observed in untreated AS cases to that of healthy controls, including several important bacterial species that have been previously associated with AS and other related diseases. Enrichment of bacterial peptides homologous to HLA-B27-presented epitopes was observed in the stools of patients with AS, suggesting that either HLA-B27 fails to clear these or that they are involved in driving HLA-B27-associated immune reactions. TNFi therapy largely restored the perturbed microbiome observed in untreated AS cases to that of healthy controls, including several important bacterial species that have been previously associated with AS and other related diseases. TNFi therapy of patients with AS was also associated with a reduction of potentially arthritogenic bacterial peptides, relative to untreated patients.
CONCLUSION: These findings emphasise the key role that the gut microbiome plays in driving the pathogenesis of AS and highlight potential therapeutic and/or preventative targets. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Ankylosing Spondylitis; Anti-TNF; Spondyloarthritis

Year:  2019        PMID: 31662318     DOI: 10.1136/annrheumdis-2019-215763

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

Review 1.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 2.  Psoriatic arthritis from a mechanistic perspective.

Authors:  Georg Schett; Proton Rahman; Christopher Ritchlin; Iain B McInnes; Dirk Elewaut; Jose U Scher
Journal:  Nat Rev Rheumatol       Date:  2022-05-05       Impact factor: 20.543

Review 3.  Microbiota-assisted therapy for systemic inflammatory arthritis: advances and mechanistic insights.

Authors:  Bowen Li; Bo Yang; Xiaoming Liu; Jianxin Zhao; R Paul Ross; Catherine Stanton; Hao Zhang; Wei Chen
Journal:  Cell Mol Life Sci       Date:  2022-08-06       Impact factor: 9.207

Review 4.  T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis.

Authors:  Jose Garrido-Mesa; Matthew A Brown
Journal:  Curr Rheumatol Rep       Date:  2022-10-05       Impact factor: 4.686

5.  Distinctive gut microbiomes of ankylosing spondylitis and inflammatory bowel disease patients suggest differing roles in pathogenesis and correlate with disease activity.

Authors:  P R Sternes; L Brett; J Phipps; F Ciccia; T Kenna; E de Guzman; K Zimmermann; M Morrison; G Holtmann; E Klingberg; D Mauro; C McIvor; H Forsblad-d'Elia; M A Brown
Journal:  Arthritis Res Ther       Date:  2022-07-07       Impact factor: 5.606

Review 6.  Ankylosing spondylitis: an autoimmune or autoinflammatory disease?

Authors:  Daniele Mauro; Ranjeny Thomas; Giuliana Guggino; Rik Lories; Matthew A Brown; Francesco Ciccia
Journal:  Nat Rev Rheumatol       Date:  2021-06-10       Impact factor: 20.543

Review 7.  Barrier lymphocytes in spondyloarthritis.

Authors:  Adam Berlinberg; Kristine A Kuhn
Journal:  Curr Opin Rheumatol       Date:  2020-07       Impact factor: 5.006

8.  Ankylosing spondylitis risk factors: a systematic literature review.

Authors:  Mark C Hwang; Lauren Ridley; John D Reveille
Journal:  Clin Rheumatol       Date:  2021-03-22       Impact factor: 3.650

9.  The Salivary Microbiota, Cytokines, and Metabolome in Patients with Ankylosing Spondylitis Are Altered and More Proinflammatory than Those in Healthy Controls.

Authors:  Longxian Lv; Huiyong Jiang; Ren Yan; Danyi Xu; Kaicen Wang; Qiangqiang Wang; Xiaoxiao Chen; Lanjuan Li
Journal:  mSystems       Date:  2021-06-22       Impact factor: 6.496

Review 10.  The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights.

Authors:  Zoya Qaiyum; Melissa Lim; Robert D Inman
Journal:  Semin Immunopathol       Date:  2021-02-24       Impact factor: 11.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.